KR101700062B9 - 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 - Google Patents

안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Info

Publication number
KR101700062B9
KR101700062B9 KR1020157033633A KR20157033633A KR101700062B9 KR 101700062 B9 KR101700062 B9 KR 101700062B9 KR 1020157033633 A KR1020157033633 A KR 1020157033633A KR 20157033633 A KR20157033633 A KR 20157033633A KR 101700062 B9 KR101700062 B9 KR 101700062B9
Authority
KR
South Korea
Prior art keywords
superstructures
arb
blocker
dual
pharmaceutical compositions
Prior art date
Application number
KR1020157033633A
Other languages
English (en)
Other versions
KR20150139624A (ko
KR101700062B1 (ko
Inventor
술리만 알-파요우미
지아휘 후
나트라잔 쿠마라페루말
알랜 에드워드 로이스
콜린 루거
에리카 아이나 자누
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101700062(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150139624A publication Critical patent/KR20150139624A/ko
Application granted granted Critical
Publication of KR101700062B1 publication Critical patent/KR101700062B1/ko
Publication of KR101700062B9 publication Critical patent/KR101700062B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157033633A 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 KR101700062B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06
US60/985,668 2007-11-06
KR1020107009852A KR101589317B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107009852A Division KR101589317B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Publications (3)

Publication Number Publication Date
KR20150139624A KR20150139624A (ko) 2015-12-11
KR101700062B1 KR101700062B1 (ko) 2017-01-26
KR101700062B9 true KR101700062B9 (ko) 2022-11-23

Family

ID=40451030

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107009852A KR101589317B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물
KR1020157033633A KR101700062B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020107009852A KR101589317B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Country Status (34)

Country Link
US (3) US20100267786A1 (ko)
EP (4) EP2217205B1 (ko)
JP (2) JP5653218B2 (ko)
KR (2) KR101589317B1 (ko)
CN (2) CN101848700A (ko)
AR (1) AR069184A1 (ko)
AU (1) AU2008324878B2 (ko)
BR (1) BRPI0823505A2 (ko)
CA (1) CA2703598C (ko)
CL (1) CL2008003298A1 (ko)
CY (2) CY1116280T1 (ko)
DK (3) DK3067043T3 (ko)
EC (1) ECSP10010160A (ko)
ES (3) ES2536514T3 (ko)
FI (1) FI3067043T3 (ko)
GT (1) GT201000131A (ko)
HK (3) HK1143529A1 (ko)
HR (3) HRP20230178T3 (ko)
HU (2) HUE028866T2 (ko)
IL (3) IL262990B2 (ko)
JO (1) JOP20080499B1 (ko)
MA (1) MA31797B1 (ko)
MX (1) MX2010004930A (ko)
MY (1) MY153730A (ko)
NZ (1) NZ584686A (ko)
PE (2) PE20091390A1 (ko)
PL (3) PL2217205T3 (ko)
PT (3) PT3067043T (ko)
RU (1) RU2493844C3 (ko)
SG (1) SG185951A1 (ko)
SI (3) SI2295035T1 (ko)
TN (1) TN2010000200A1 (ko)
TW (1) TWI484982B (ko)
WO (1) WO2009061713A1 (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3067043T (pt) 2007-11-06 2023-03-01 Novartis Ag Composições farmacêuticas baseadas em superestruturas de antagonista/bloqueador de receptores da angiotensina (arb) e inibidores da endopeptidase neutra (nep)
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
BRPI1011657A2 (pt) 2009-05-28 2019-04-16 Novartis Ag derivados aminopropiônicos substituídos como inibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
KR101864865B1 (ko) * 2010-08-24 2018-06-05 노파르티스 아게 항응고제 요법을 받고 있는 포유동물에서의 고혈압의 치료 및／또는 심부전의 예방 또는 치료
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
CN105008337B (zh) 2013-02-14 2017-08-04 诺华股份有限公司 具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
ES2767084T3 (es) 2013-08-26 2020-06-16 Novartis Ag Nuevo uso
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
EP3229799B1 (en) 2014-12-08 2018-10-17 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
ES2945866T3 (es) 2015-05-11 2023-07-10 Novartis Ag Pauta posológica de sacubitrilo-valsartán para el tratamiento de la insuficiencia cardíaca
JP2018516267A (ja) 2015-05-29 2018-06-21 ノバルティス アーゲー 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
ES2890573T3 (es) * 2017-03-31 2022-01-20 Tiefenbacher Alfred E Gmbh & Co Kg Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) * 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US11877576B2 (en) 2018-06-22 2024-01-23 Ideaz, Llc Diphenyl tablets and methods of preparing the same
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607355A (en) 1898-07-12 Carrier for bicycles
US607893A (en) 1898-07-26 Automatic switch-operating machine
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
IL136142A0 (en) * 1997-11-17 2001-05-20 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6558699B2 (en) 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PT1087775E (pt) * 1998-06-17 2005-11-30 Bristol Myers Squibb Co Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos
SK9132001A3 (en) * 1998-12-23 2002-01-07 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL153882A0 (en) 2000-07-19 2003-07-31 Novartis Ag Valsartan salts
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
ATE370732T1 (de) 2002-01-17 2007-09-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
AU2003223637A1 (en) 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
JP2009513543A (ja) 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AU2006307470A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
US20080227836A1 (en) 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
WO2007056342A2 (en) 2005-11-07 2007-05-18 Stryker Corporation Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration
RU2008122712A (ru) 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PT3067043T (pt) 2007-11-06 2023-03-01 Novartis Ag Composições farmacêuticas baseadas em superestruturas de antagonista/bloqueador de receptores da angiotensina (arb) e inibidores da endopeptidase neutra (nep)

Also Published As

Publication number Publication date
KR20100085087A (ko) 2010-07-28
EP4186491A1 (en) 2023-05-31
SI2295035T1 (sl) 2016-09-30
CA2703598A1 (en) 2009-05-14
MA31797B1 (fr) 2010-10-01
AR069184A1 (es) 2010-01-06
DK2217205T3 (en) 2015-05-11
ECSP10010160A (es) 2010-06-29
HK1149721A1 (zh) 2011-10-14
TWI484982B (zh) 2015-05-21
IL205208A0 (en) 2010-12-30
GT201000131A (es) 2012-04-30
WO2009061713A1 (en) 2009-05-14
NZ584686A (en) 2013-03-28
CL2008003298A1 (es) 2009-06-26
TW200936183A (en) 2009-09-01
CN101848700A (zh) 2010-09-29
US20100267786A1 (en) 2010-10-21
KR101589317B1 (ko) 2016-01-28
FI3067043T3 (fi) 2023-03-18
ES2536514T3 (es) 2015-05-26
PL2295035T3 (pl) 2016-11-30
MY153730A (en) 2015-03-13
IL262990A (en) 2018-12-31
US20210085631A1 (en) 2021-03-25
EP2295035A2 (en) 2011-03-16
PT2295035T (pt) 2016-08-22
IL262990B2 (en) 2023-10-01
ES2587336T3 (es) 2016-10-24
DK2295035T3 (en) 2016-08-29
CY1117883T1 (el) 2017-05-17
EP3067043B1 (en) 2022-11-30
JP2011503082A (ja) 2011-01-27
KR101589317B9 (ko) 2022-11-23
JP2015038069A (ja) 2015-02-26
HUE061321T2 (hu) 2023-06-28
HRP20160988T1 (hr) 2016-10-07
CY1116280T1 (el) 2017-03-15
SI3067043T1 (sl) 2023-04-28
PL2217205T3 (pl) 2015-07-31
IL249922A0 (en) 2017-03-30
AU2008324878A1 (en) 2009-05-14
ES2939163T3 (es) 2023-04-19
CA2703598C (en) 2016-08-09
BRPI0823505A2 (pt) 2015-06-16
EP2295035A3 (en) 2012-08-08
HRP20230178T3 (hr) 2023-03-31
EP2217205B1 (en) 2015-03-04
MX2010004930A (es) 2010-05-27
EP3067043A1 (en) 2016-09-14
RU2493844C3 (ru) 2017-07-05
KR20150139624A (ko) 2015-12-11
KR101700062B1 (ko) 2017-01-26
HK1224195A1 (zh) 2017-08-18
HRP20150459T1 (hr) 2015-07-17
PE20091390A1 (es) 2009-10-13
CN103251587A (zh) 2013-08-21
PE20141072A1 (es) 2014-09-10
JOP20080499B1 (ar) 2022-09-15
HK1143529A1 (en) 2011-01-07
TN2010000200A1 (en) 2011-11-11
EP2217205A1 (en) 2010-08-18
EP2295035B1 (en) 2016-05-18
IL262990B1 (en) 2023-06-01
PL3067043T3 (pl) 2023-05-08
DK3067043T3 (da) 2023-02-27
US20240115536A1 (en) 2024-04-11
PT3067043T (pt) 2023-03-01
JP5653218B2 (ja) 2015-01-14
RU2493844C2 (ru) 2013-09-27
RU2010123027A (ru) 2011-12-20
SI2217205T1 (sl) 2015-10-30
HUE028866T2 (en) 2017-01-30
AU2008324878B2 (en) 2013-04-18
PT2217205E (pt) 2015-06-08
IL205208A (en) 2017-01-31
SG185951A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
IL262990A (en) Dual-activity pharmaceutical compositions based on angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor superstructures
HUS2100003I1 (hu) Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja
ZA200901694B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
HUS1800044I1 (hu) Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére
PL2059246T3 (pl) Kompozycje terapeutyczne zawierające swoistego antagonistę receptora endoteliny i inhibitor pde5
PL2252273T3 (pl) Stała kompozycja farmaceutyczna zawierająca niepeptydowy związek antagonistyczny receptora angiotensyny II i środek moczopędny
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
ZA200903523B (en) Poly-TLR antagonist
ZA200704717B (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
ZA200902164B (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 4

J204 Request for invalidation trial [patent]
J204 Request for invalidation trial [patent]
J204 Request for invalidation trial [patent]
J206 Request for trial to confirm the scope of a patent right
J121 Written withdrawal of request for trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001529; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220531

J121 Written withdrawal of request for trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001519; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220803

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001566; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001565; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001564; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001563; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001558; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001557; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001555; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001554; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001552; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001551; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001549; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001548; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001546; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001545; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001543; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001542; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001540; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001539; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001532; TRIAL DECISION FOR INVALIDATION REQUESTED 20210521

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001523; TRIAL DECISION FOR INVALIDATION REQUESTED 20210521

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001504; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001503; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001502; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001501; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001500; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001499; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001498; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001366; TRIAL DECISION FOR INVALIDATION REQUESTED 20210507

Effective date: 20220809